| Nov 3 |
Anika Therapeutics, Inc. (ANIK) Q3 2024 Earnings Call Transcript
|
| Nov 1 |
Anika Therapeutics Third Quarter 2024 Earnings: Misses Expectations
|
| Nov 1 |
Anika Therapeutics Inc (ANIK) Q3 2024 Earnings Call Highlights: Strategic Shifts Amid Revenue ...
|
| Oct 31 |
Arthrosurface Returns to it Roots Following Divestiture from Anika Therapeutics
|
| Oct 31 |
Anika Therapeutics (ANIK) Reports Q3 Loss, Lags Revenue Estimates
|
| Oct 31 |
Anika Therapeutics Non-GAAP EPS of -$0.25, revenue of $38.8M
|
| Oct 31 |
Anika: Q3 Earnings Snapshot
|
| Oct 31 |
Anika Reports Third Quarter 2024 Financial Results
|
| Oct 31 |
Anika Announces Strategic Update of Business with Sale of Arthrosurface and Plan to Divest Parcus Medical
|
| Oct 30 |
Investors in Anika Therapeutics (NASDAQ:ANIK) have unfortunately lost 61% over the last five years
|
